Safety and efficacy of two reduced dosing regimens of sodium phosphate tablets for preparation prior to colonoscopy

Douglas Rex, R. Chasen, M. B. Pochapin

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Objectives: To evaluate the safety and efficacy of two reduced dosing regimens of sodium phosphate tablets (Visicol, InKine Pharmaceutical Co. Inc., Blue Bell, PA, USA) for colon cleansing prior to colonoscopy. Methods: In a randomized, multicentre, endoscopist-blinded clinical study, adults undergoing colonoscopy received either 28 tablets (42 g) or 32 tablets (48 g) of sodium phosphate for colon cleansing. The endoscopist used a validated four-point scale to rate the overall quality of colon cleansing as well as cleansing in the ascending colon. Adverse events were collected and evaluated. Results: The quality of overall colon cleansing was 'excellent' or 'good' in 84% or more of both groups, with no significant difference between the two doses. No patient had a preparation rated as 'inadequate' or required a repeat procedure. All patients were able to complete the assigned dose of tablets, and there were no deaths, serious adverse events or dropouts from the study. Conclusions: A reduced tablet regimen for sodium phosphate tablets, using either 28 or 32 tablets, is well tolerated and effective for colon cleansing prior to colonoscopy.

Original languageEnglish
Pages (from-to)937-944
Number of pages8
JournalAlimentary Pharmacology and Therapeutics
Volume16
Issue number5
DOIs
StatePublished - 2002

Fingerprint

Colonoscopy
Tablets
Safety
Colon
Ascending Colon
sodium phosphate
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Safety and efficacy of two reduced dosing regimens of sodium phosphate tablets for preparation prior to colonoscopy. / Rex, Douglas; Chasen, R.; Pochapin, M. B.

In: Alimentary Pharmacology and Therapeutics, Vol. 16, No. 5, 2002, p. 937-944.

Research output: Contribution to journalArticle

@article{d7e89aff6b01483db3a77709b0cab8e8,
title = "Safety and efficacy of two reduced dosing regimens of sodium phosphate tablets for preparation prior to colonoscopy",
abstract = "Objectives: To evaluate the safety and efficacy of two reduced dosing regimens of sodium phosphate tablets (Visicol, InKine Pharmaceutical Co. Inc., Blue Bell, PA, USA) for colon cleansing prior to colonoscopy. Methods: In a randomized, multicentre, endoscopist-blinded clinical study, adults undergoing colonoscopy received either 28 tablets (42 g) or 32 tablets (48 g) of sodium phosphate for colon cleansing. The endoscopist used a validated four-point scale to rate the overall quality of colon cleansing as well as cleansing in the ascending colon. Adverse events were collected and evaluated. Results: The quality of overall colon cleansing was 'excellent' or 'good' in 84{\%} or more of both groups, with no significant difference between the two doses. No patient had a preparation rated as 'inadequate' or required a repeat procedure. All patients were able to complete the assigned dose of tablets, and there were no deaths, serious adverse events or dropouts from the study. Conclusions: A reduced tablet regimen for sodium phosphate tablets, using either 28 or 32 tablets, is well tolerated and effective for colon cleansing prior to colonoscopy.",
author = "Douglas Rex and R. Chasen and Pochapin, {M. B.}",
year = "2002",
doi = "10.1046/j.1365-2036.2002.01259.x",
language = "English",
volume = "16",
pages = "937--944",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Safety and efficacy of two reduced dosing regimens of sodium phosphate tablets for preparation prior to colonoscopy

AU - Rex, Douglas

AU - Chasen, R.

AU - Pochapin, M. B.

PY - 2002

Y1 - 2002

N2 - Objectives: To evaluate the safety and efficacy of two reduced dosing regimens of sodium phosphate tablets (Visicol, InKine Pharmaceutical Co. Inc., Blue Bell, PA, USA) for colon cleansing prior to colonoscopy. Methods: In a randomized, multicentre, endoscopist-blinded clinical study, adults undergoing colonoscopy received either 28 tablets (42 g) or 32 tablets (48 g) of sodium phosphate for colon cleansing. The endoscopist used a validated four-point scale to rate the overall quality of colon cleansing as well as cleansing in the ascending colon. Adverse events were collected and evaluated. Results: The quality of overall colon cleansing was 'excellent' or 'good' in 84% or more of both groups, with no significant difference between the two doses. No patient had a preparation rated as 'inadequate' or required a repeat procedure. All patients were able to complete the assigned dose of tablets, and there were no deaths, serious adverse events or dropouts from the study. Conclusions: A reduced tablet regimen for sodium phosphate tablets, using either 28 or 32 tablets, is well tolerated and effective for colon cleansing prior to colonoscopy.

AB - Objectives: To evaluate the safety and efficacy of two reduced dosing regimens of sodium phosphate tablets (Visicol, InKine Pharmaceutical Co. Inc., Blue Bell, PA, USA) for colon cleansing prior to colonoscopy. Methods: In a randomized, multicentre, endoscopist-blinded clinical study, adults undergoing colonoscopy received either 28 tablets (42 g) or 32 tablets (48 g) of sodium phosphate for colon cleansing. The endoscopist used a validated four-point scale to rate the overall quality of colon cleansing as well as cleansing in the ascending colon. Adverse events were collected and evaluated. Results: The quality of overall colon cleansing was 'excellent' or 'good' in 84% or more of both groups, with no significant difference between the two doses. No patient had a preparation rated as 'inadequate' or required a repeat procedure. All patients were able to complete the assigned dose of tablets, and there were no deaths, serious adverse events or dropouts from the study. Conclusions: A reduced tablet regimen for sodium phosphate tablets, using either 28 or 32 tablets, is well tolerated and effective for colon cleansing prior to colonoscopy.

UR - http://www.scopus.com/inward/record.url?scp=0036234666&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036234666&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2036.2002.01259.x

DO - 10.1046/j.1365-2036.2002.01259.x

M3 - Article

VL - 16

SP - 937

EP - 944

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 5

ER -